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although it was unclear whether these were prescribed for axial or pe-
ripheral symptoms.
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A xial spondyloarthritis (SpA) is characterized by inflamma-tion of the spine and sacroiliac (SI) joints.1 Historically,
according to modified New York criteria, radiographic evidence
of structural damage to the SI joints (radiographic sacroiliitis)
was required to identify patients with predominantly axial forms
of SpA, diagnosed as ankylosing spondylitis (AS).2 However,
there are patients who may have signs and symptoms typical of
AS, but who lack radiographic sacroiliitis, and are now classified
as having nonradiographic axial SpA (nr-axSpA).3,4
Subsequently, the Amor criteria5 and the European Spondy-
loarthropathy Study Group (ESSG) criteria6 sought to extend the
definition of SpA beyond those with the mandatory radiographic
sacroiliitis.
On average, 6 to 8 years elapse between the onset of chronic
back pain and a diagnosis of AS based on radiographic evidence.7
In an effort to reduce the delay in diagnosis, the Assessment of
SpondyloArthritis International Society (ASAS) expanded its
classification criteria to encompass nr-axSpA.3,4 Patients with
chronic back pain (≥3 months) that started before 45 years of
age can be classified as having axial SpA either by sacroiliitis
on imaging (either magnetic resonance imaging [MRI] or radio-
graph) plus 1 or more feature typical of SpA or the presence of
human leukocyte antigen B27 (HLA-B27) plus 2 or more other
SpA features.4 Based on these criteria, ASAS more recently pro-
posed a diagnostic algorithm that can be applied in daily clinical
practice.8 Despite these advancements, a delay in diagnosis may
still occur because of infrequent referrals by other physicians to
a rheumatologist. Referral strategies for SpA have been shown
to lead to proper diagnosis in a high proportion of patients,9 but
referral patterns have not been well studied.
Treatment recommendations for the management of AS have
existed for several years.10,11 In 2010, the ASAS and the European
League Against Rheumatology updated their recommendations
for the management of AS, and ASAS updated the recommenda-
tions on treatment with tumor necrosis factor (TNF) inhibitors to
include all axial SpA patients (AS and nr-axSpA).12,13 Nonsteroidal
anti-inflammatory drugs (NSAIDs) are recommended as first-line
treatment for patients with axial SpA.12,13 Prior to initiating anti-
TNF therapy, the ASAS recommendations advocate that patients
with axial SpA undergo mandatory treatment with 2 or more
NSAIDs for a total of 4 weeks or more.13 Disease-modifying anti-
rheumatic drugs (DMARDs) are not recommended for the manage-
ment of axial disease because of the lack of clinical evidence.
Appropriate identification and referral of patients with symp-
toms suggestive of axial SpA can facilitate earlier diagnosiser 2014 www.jclinrheum.com 411
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ternational and Multicentric Approaches) survey was conducted
to understand current referral practices and to identify areas for
improvement. The MAXIMA survey also evaluated the use of
diagnostic tools and management of axial SpA among rheumatol-
ogists. An additional objective was to identify similarities and
differences in referral, diagnosis, and disease management among
rheumatologists in academic settings compared with those in com-
munity practices, as well as among rheumatologists in Western
Europe (WE), North America (NA), and regions throughout the rest
of the world (RoW).
METHODS
TheMAXIMA survey was drafted and conducted by a third-
party vendor (excluding the United States: Margaux Orange,
Paris, France; United States: Instar, New York) with guidance
and approval of the questionnaire by members of a steering
committee whose members were selected based on their expertise
in the field of SpA: Désirée van der Heijde (the Netherlands),
Ruben Burgos-Vargas (Mexico), Eduardo Collantes (Spain), Atul
Deodhar (United States), Dirk Elewaut (Belgium), Robert Inman
(Canada), Helena Marzo-Ortega (United Kingdom), Philip Mease
(United States), Ignazio Olivieri (Italy), Thao Pham (France), and
Joachim Sieper (Germany). Questions pertaining to referral,
diagnosis, and management of patients with chronic back pain
(≥3 months) that started before 45 years of age were developed,
reviewed, and approved by the steering committee. The survey
questions were not pretested or validated. The MAXIMA survey
was funded by AbbVie Inc. Surveys were completed anonymously
online by rheumatologists from NA, Latin America, Europe, Asia-
Pacific, Africa, and the Middle East. The survey was conducted
from November 2011 to December 2011, except in the United
States, where the survey was conducted in May 2012. Some
questions in the US survey were adapted to match the unique
requirements of the US medical system and differed slightly from
the surveys used in all other countries. In the United States,
respondents were compensated to complete the survey, whereas
respondents outside the United States were not compensated for
completing the survey.
There was no prespecified goal for the number of surveys
to be completed. Results from MAXIMA were summarized
descriptively and reported as the percentages of respondents in
each survey. The MAXIMA steering committee advisory board
reviewed the survey results. Steering committee members specif-
ically reviewed and advised AbbVie on the content of their




The MAXIMA survey was completed by 809 rheumato-
logists from 56 countries (for individual country listing, see
Supplementary Table, http://links.lww.com/RHU/A44). In WE,
the survey was completed by 258 rheumatologists: 71 rheumatolo-
gists (28%) were in academic practice settings, and 187 rheuma-
tologists (72%) were in community practice settings. In NA,
154 surveys were completed by rheumatologists in the United
States (academic centers, 34%; community practice, 66%), and 36
surveys were completed by rheumatologists in Canada (academic
centers, 25%; community practice, 75%). In the RoW, the survey
was completed by 361 rheumatologists: 72 rheumatologists (20%)
were in academic practice settings, and 289 rheumatologists (80%)
were in community practice settings.412 www.jclinrheum.comReferral Patterns
For patients with chronic back pain (≥3 months) that started
before 45 years of age, the majority of rheumatologists reported
that primary care providers were the main source of referral
(Table 1). Responses regarding source of referrals of patients with
axial SpAwere generally similar in both academic and community
clinic practice settings.
Symptoms triggering referral of patients to rheumatolo-
gists were surveyed only in questionnaires conducted outside the
United States. Overall, symptoms that most frequently triggered
referrals to a rheumatologist were uveitis (range, 78%–89%) and
chronic back pain (range, 58%–78%). Rates reported by academic
and community rheumatologists were generally similar. The
duration of symptoms among referred patients did not differ
markedly by rheumatologists’ practice site (Supplementary Figure 1,
http://links.lww.com/RHU/A42). Compared with WE, Canada,
and the RoW, the reported time to referral to a rheumatologist was
shorter in the United States. Few US rheumatologists stated that pa-
tients had symptoms of SpA for at least 3 years at the time of referral,
and approximatelyhalf reportedpatient referralwithin1yearof symp-
tom onset.
Diagnosis
The use of classification criteria for axial SpA is reported
in Table 1. In general, NA rheumatologists infrequently referred
to classification criteria when making a diagnosis of axial SpA
in clinical practice; use of ASAS criteria and modified New York
criteria for AS were lower for NA practitioners (27% and 17%,
respectively) compared with practitioners from other regions
(Table 1). Rates for the use of other classification criteria to guide
diagnostic evaluation were also low among NA rheumatologists
(ESSG and Amor criteria, 2% each; Table 1). The most common
reasons cited for not using ASAS criteria were “don’t use guide-
lines” (39% of US respondents [response not available in other
countries]) and “lack of awareness” (33%).
Approximately half of survey respondents in all regions re-
ported systematically requesting HLA-B27 typing when evaluat-
ing a patient with chronic back pain in their daily practice
(Table 1). North America rheumatologists in community practices
reported using HLA-B27 typing at a rate (58%) that was higher
than NA rheumatologists in academic settings, WE rheumatolo-
gists in academic or community practices, and RoW rheumatolo-
gists in community practices (46% each), but similar to that of
RoW rheumatologists in academic settings (59%). The use of
imaging tests to help guide diagnosis of axial SpAwas frequently
reported by rheumatologists across regions (Table 1). North
America rheumatologists in community practices reported a
slightly lower use of pelvic x-ray (74%) compared with NA
rheumatologists in academic settings and rheumatologists in WE
and RoW. Magnetic resonance imaging of the SI joints was more
frequently used than pelvic x-ray across all regions.
Disease Burden and Management
Rheumatologists reported that back pain was the most im-
portant disease burden cited by patients with axial SpA across
all regions (Fig. 1). Notably, quality of life followed back pain as
the second most important burden of disease in WE and RoW,
whereas stiffness was more often reported as the second most
important burden in the United States. In Canada, stiffness, fa-
tigue, and quality of life were closely matched for the second
most important burden of disease, although there was a large dif-
ference reported for quality of life between academic centers and
community practice.© 2014 Lippincott Williams & Wilkins
































Referral sources for patients
with chronic back pain,a,b %
Primary care provider 87 94 92 94 96 95 75 78 77
Physiotherapist 23 42 36 0 2 1 17 16 16
Physical/occupational
therapist
N/A N/A N/A 27 23 24 N/A N/A N/A
Chiropractor N/A N/A N/A 16 20 18 N/A N/A N/A
Another rheumatologistc 14 22 20 3 5 5 32 15 19
Other specialistd 45 48 47 35 25 28 54 49 50
Other/none 24 19 20 0 3 2 33 27 29
Classification criteria guides
for axial SpA,a,e %
ASAS 92 81 84 30f 26g 27h 92 79 82
Modified New York criteria
for AS
20 22 22 16 17 17 19 27 26
ESSG 3 12 9 5 1 2 7 9 9
Amor criteria 3 6 5 3 2 2 4 8 7
None 6 10 9 0 2 1 3 5 5
HLA-B27 typing routinely
performed for patients with
chronic back pain,i %
46 46 46 46 58 54 59 46 48
Imaging tests used for patients
with chronic back pain,a,i %
MRI SI joint 94 96 96 81 79 79 89 88 88
Pelvic x-ray 94 85 88 81 74 76 83 82 82
Spinal x-ray 72 82 79 85 80 82 74 64 66
MRI spine 59 61 60 50 53 52 46 41 42
Ultrasound 10 13 12 0 1 1 8 8 8
Other 21 40 34 13 16 15 42 29 32
aPhysicians may have selected more than 1 choice; therefore, the sum of the categories may exceed 100%.
bWE, CA, and RoW: chronic back pain refers to patients with back pain for 3 months or more starting at less than 45 years of age. Physical/occupational
therapist and chiropractor were choices available only in the United States; physiotherapist was not available as a choice in the United States.
cRefers to private office rheumatologists in the WE, CA, and RoW survey.
dWE, CA, and RoW: “other specialist” includes dermatologists, gastroenterologists, and ophthalmologists; US: “other specialist” includes orthopedists,
pain management specialists, and psychiatrists.
eAcademic center, n = 61; community clinical practice, n = 124; overall, n = 185; none was not a possible response in the United States.
fUS: 19%; CA: 89%.
gUS: 11%; CA: 78%.
hUS: 14%; CA: 81%.
iWE: academic center, n = 71; community clinical practice, n = 185; overall, n = 256. NA: academic center, n = 50; community clinical practice, n = 106;
overall, n = 156. RoW: academic center, n = 69; community clinical practice: n = 285; overall, n = 354.
CA indicates Canada; N/A, question not available on survey for this group.
JCR: Journal of Clinical Rheumatology • Volume 20, Number 8, December 2014 Referral, Diagnosis, and Management of Axial SpAIn the MAXIMA survey, most rheumatologists reported pre-
scribing 1 to 2 courses of NSAIDs before considering a treatment
class change (Fig. 2). However, Canadian rheumatologists applied
a more conservative approach, especially in academic settings,
where 63% of rheumatologists prescribed at least 3 courses of
NSAIDs. Most rheumatologists reported that they would evaluate
the efficacy of NSAIDs after 1 to 3 months of therapy (Supple-
mentary Figure 2, http://links.lww.com/RHU/A43). Trends in© 2014 Lippincott Williams & Wilkinsprescribing and evaluating the efficacy of NSAIDs were generally
similar among academic and community rheumatologists.
Most respondents in academic or community practice set-
tings, independent of location, reported prescribing DMARDs
for the management of axial SpA. Sulfasalazine was the most
commonly prescribed DMARD for AS and nr-axSpA across most
regions (Fig. 3). Methotrexate was more frequently prescribed by
rheumatologists in the United States (AS, 76%–81%; nr-axSpA,www.jclinrheum.com 413
FIGURE 1. Rates reported for the top 3 burden of disease concerns
among axial SpA patients in WE (A), NA (B), and RoW (C).
Rheumatologists in all countries except the United States responded
to the following survey question: What do you consider as the top 3
item(s) of the burden of disease among your axial SpA patients? US
rheumatologists responded to the following survey question: What
do you consider the top 3 burden of disease concerns among your
nr-axSpA patients? QoL indicates quality of life.
van der Heijde et al JCR: Journal of Clinical Rheumatology • Volume 20, Number 8, December 201469%–81%) compared withWE (AS, 51%–68%; nr-axSpA, 51%–
70%); rates of prescribing methotrexate were particularly low
among RoW rheumatologists (AS, 35%–56%; nr-axSpA, 47%–
50%). “Other DMARDs” (which included leflunomide,
hydroxychloroquine, and antimalarials) were prescribed more fre-
quently by US and Canadian rheumatologists compared with WE
and RoW.FIGURE 2. Nonsteroidal anti-inflammatory drugs in the
management of AS in WE (A), NA (B), and RoW (C). Proportions
of rheumatologists prescribing different courses of NSAIDs for AS
before considering a treatment class change. Rheumatologists in all
countries except the United States responded to the following
question: Considering those patients diagnosed with AS, howmany
courses of NSAIDs do you prescribe before considering a treatment
class change?US rheumatologists responded to the following survey
question: When thinking about your AS patient, howmany different
NSAIDs do you prescribe before considering a treatment class
change? *1% selected “other.”DISCUSSION
Results of the MAXIMA survey demonstrated general agree-
ment in referral patterns, diagnosis, and management of axial SpA
among rheumatologists in WE, NA, and RoW, with some differ-
ences noted for the time to referral to a rheumatologist, use of
classification criteria, NSAID courses before treatment change,
and DMARD use. Furthermore, practice patterns for axial SpA
were generally similar in academic and community clinic settings.414 www.jclinrheum.comReferral to a rheumatologist is one of the first steps toward
an accurate and timely diagnosis. Although time to referral was
not based on a precise measurement and may have been influ-
enced by recall bias, survey results showed that the reported time
to referral was longer inWE and RoW, with approximately half of
patients referred to rheumatologists for evaluation several years
after the onset of symptoms. In contrast, the majority of patients
in the United States were referred to rheumatologists within
2 years. This finding is unexpected, as it is frequently stated that
rheumatologists in the United States do not see patients with back
pain early. Differences in national health care systems, the pres-
ence of additional medical specialties in the United States (eg,
physical medicine and rehabilitation, chiropractors), and the low
number of rheumatologists per capita in countries such as
Germany may have contributed to the regional differences in the time
to referral.© 2014 Lippincott Williams & Wilkins
FIGURE 3. Rates of DMARD use among rheumatologists prescribing DMARDs for themanagement of AS and nr-axSpA inWE (A), NA (B), and
RoW (C). “Other DMARDs” include leflunomide, hydroxychloroquine, and antimalarials. Rheumatologists in all countries except the
United States responded to the following questions: (1) Considering those patients diagnosed with AS, do you use DMARDs in AS? If yes,
please specifywhich one(s). (2) If you dodifferentially treat nr-axSpA patients, do you use DMARDs in nr-axSpA treatment? US rheumatologists
responded to the following survey questions: (1) When thinking about your AS patient, which DMARDs do you prescribe? (2) Please specify
which DMARD(s) you use for nr-axSpA treatment. *In responses where the percentage was greater than 100%, more respondents answered
the question regarding which type of DMARDwas used (numerator for calculation) than respondents who answered the question regarding if
they used DMARDs (denominator for calculation), resulting in a percentage greater than 100%.
JCR: Journal of Clinical Rheumatology • Volume 20, Number 8, December 2014 Referral, Diagnosis, and Management of Axial SpAAlthough these results suggest a need for improvement, time
to referral has decreased over the past several years. In 1988,
Kidd and Cawley14 reported that patients with SpA in the United
Kingdom had experienced multiple referrals and delayed diagnosis.
The median time from first symptom to diagnosis for patients
referred to nonrheumatologists and rheumatologists was 6 years
and 3 years, respectively.14 In Germany, the average delay from
first AS symptoms to diagnosis decreased from 15 years in patients
with disease onset in the 1950s, to approximately 7.5 years for
patients with SpA onset between 1975 and 1979.15
Survey results showed that rheumatologists prefer imaging
tests, especially MRI, over HLA-B27 testing for the diagnosis of
axial SpA. In our survey, only approximately half of the rheuma-
tologists stated that they used HLA-B27 assessments in making© 2014 Lippincott Williams & Wilkinsthe diagnosis. The slow uptake of the HLA-B27 test might be
explained by the lack of understanding of its positive predictive
value for making the diagnosis of axial SpA in a suitable patient.
Moreover, it shows that there is a stronger belief in imaging in
the diagnostic process.
The ability to detect sacroiliitis on MRI has been shown to
substantially contribute to transitioning patients from an undiffer-
entiated status to a diagnosis of axial SpA.3 Magnetic resonance
imaging of the SI joints was widely used by WE, NA, and RoW
rheumatologists, regardless of practice setting. A high level of
awareness and utilization of the ASAS axial SpA classification
criteria was identified among WE and RoW rheumatologists,
whereas use of the ASAS criteria was lower among NA rheuma-
tologists. Reasons for not using ASAS classification criteria citedwww.jclinrheum.com 415
van der Heijde et al JCR: Journal of Clinical Rheumatology • Volume 20, Number 8, December 2014by NA rheumatologists included lack of awareness and, in the
United States, not using guidelines in general. Another possible
explanation for lower use of ASAS criteria in NA may be that
in Europe and other parts of the world, the ESSG and Amor
criteria have been used since 1991 to identify nr-axSpA patients,
whereas this was generally not the case in the United States. In
the United States, radiographic changes have remained a more
crucial component for classification. In addition, more than a third
of US rheumatologists reported that they “don’t use guidelines.”
This response by US rheumatologists compared with the other
survey respondents may be a result of interpretation of the word-
ing. Classification criteria are meant to be a guide, not a strict
application for diagnosis. The wording of the questionnaire may
have been such that US rheumatologists were reluctant to answer
a question that contradicts good clinical practice or may have had
difficulty with the word “guidelines” rather than “criteria.”
Disease management approaches used for AS and nr-axSpA
were generally similar across geographic regions. Consistent with
recent recommendations,12,13 most rheumatologists prescribed 1
to 2 courses of NSAIDs and evaluated efficacy after 1 to 3 months
before considering a treatment class change. The differences
noted in Canada are a reflection of the Canadian Rheumatologists
Association/Spondyloarthritis Research Consortium of Canada
guidelines that require the use of at least 3 NSAIDs, each admin-
istered over a minimum 2-week period.16 The use of DMARDs
for axial symptoms prior to anti-TNF therapy is not recommended
byASAS/European LeagueAgainst Rheumatology recommenda-
tions because of the lack of evidence that these medications can
improve the signs and symptoms of axial disease.12,13 Despite
these recommendations, the majority of rheumatologists partici-
pating in this survey prescribed DMARDs for patients with AS
and nr-axSpA, suggesting the need for additional effective thera-
pies for axial SpA and further education. Furthermore, it is unclear
if DMARDs were prescribed for patients with pure axial disease
or for peripheral symptoms in patients with axial disease.
One notable disparity in disease management was the
more frequent use of methotrexate among US rheumatologists
compared with WE and RoW rheumatologists. Furthermore,
WE and RoW rheumatologists prescribed sulfasalazine more fre-
quently than methotrexate for the treatment of AS and nr-axSpA,
whereas rates of the use of sulfasalazine and methotrexate were
similar among US rheumatologists. Similar to rheumatoid arthri-
tis, historically, the use of methotrexate has been higher than
sulfasalazine in the United States,17 whereas the converse has
been true in other countries. Methotrexate could also have been
used in the United States as a combination therapy with TNF
inhibitors to reduce anti–drug antibody production, although this
information was not collected.
The MAXIMA survey had more than 800 participants from
56 countries across the world, allowing for a robust analysis of
referral, disease, and axial SpA patient management. In addition,
both academic and community clinic rheumatologists were repre-
sented. The data were not derived from a clinical study with
follow-up and data verification. Limitations of the current survey
include the selection of respondents and survey questions by the
study sponsor and the slightly different phrasing of some survey
questions in the US questionnaire compared with the question-
naire used in all of the other countries, allowing only limited
comparisons for some of the questions. Furthermore, US respon-
dents, but not respondents from other countries, were compen-
sated for completing the survey, potentially affecting responses.
In summary, there is increasing awareness of axial SpA, but
delays in referral and diagnosis persist. The delay from symptom
onset to referral and diagnosis of axial SpA highlights the need
for continuing education of both referring health care providers416 www.jclinrheum.comand rheumatologists to improve axial SpA recognition in appro-
priate patients with chronic back pain. Although some differences
exist across geographic regions, rheumatologists in academic and
community clinical practice settings used similar disease manage-
ment approaches for axial SpA. Despite the lack of evidence of the
efficacy of DMARDs in treating axial symptoms, DMARDs were
commonly prescribed for patients with axial SpA. Although it was
unclear whether the DMARDs were intended to treat axial or pe-
ripheral symptoms, or whether patients presented with peripheral
symptoms, this observation suggests the need for more effective
treatment options for this disease and further education regarding
management. Overall, the results highlight the need for further
education to facilitate early diagnosis and referral of patients with
axial SpA, as well as to increase awareness of therapies recom-
mended for the management of axial SpA.
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